^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PLK1 inhibitor

    Related drugs:
    Apply
    Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors (NCT05764395)
    Phase 2
    Vanderbilt-Ingram Cancer Center
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    05/09/2023
    Primary completion :
    05/01/2028
    Completion :
    05/01/2029
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • Estybon (rigosertib)
    Onvansertib + Paclitaxel In TNBC (NCT05383196)
    Phase 1/2
    Antonio Giordano, MD
    Recruiting
    Last update posted :
    05/20/2024
    Initiation :
    09/30/2022
    Primary completion :
    02/15/2026
    Completion :
    02/15/2029
    HER-2
    |
    HER-2 negative
    |
    paclitaxel • onvansertib (PCM-075)
    Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment (NCT04263090)
    Phase 1/2
    Icahn School of Medicine at Mount Sinai
    Completed
    Last update posted :
    05/09/2024
    Initiation :
    06/29/2020
    Primary completion :
    12/20/2023
    Completion :
    12/20/2023
    KRAS
    |
    KRAS mutation
    |
    Opdivo (nivolumab) • Estybon (rigosertib)
    Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation (NCT06106308)
    Phase 2
    Cardiff Oncology
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    02/27/2024
    Primary completion :
    11/01/2026
    Completion :
    01/01/2027
    KRAS • NRAS
    |
    KRAS mutation • NRAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • onvansertib (PCM-075)
    Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation (NCT03829410)
    Phase 1/2
    Cardiff Oncology
    Completed
    Last update posted :
    03/01/2024
    Initiation :
    05/06/2019
    Primary completion :
    01/29/2024
    Completion :
    01/29/2024
    KRAS • BRAF
    |
    KRAS mutation • BRAF mutation • KRAS exon 2 mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)
    Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer (NCT04446793)
    Phase N/A
    Cardiff Oncology
    No Longer Available
    Last update posted :
    02/12/2024
    KRAS
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)
    A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma (NCT05358379)
    Phase 1/2
    Cyclacel Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    04/14/2022
    Primary completion :
    08/01/2025
    Completion :
    11/01/2025
    PLK1 • CDKN1A
    |
    MYC expression
    Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation (ONSEMBLE) (NCT05593328)
    Phase 2
    Cardiff Oncology
    Active, not recruiting
    Last update posted :
    01/17/2024
    Initiation :
    03/17/2023
    Primary completion :
    11/01/2025
    Completion :
    04/01/2026
    KRAS • NRAS
    |
    NRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)
    Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer (NCT00710710)
    Phase 2
    Boehringer Ingelheim
    Completed
    Last update posted :
    05/04/2022
    Initiation :
    08/01/2006
    Primary completion :
    10/14/2008
    Completion :
    10/14/2008
    CA 19-9
    |
    BI2536
    Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin (NCT00861328)
    Phase 1
    Onconova Therapeutics, Inc.
    Completed
    Last update posted :
    06/23/2017
    Initiation :
    02/01/2008
    Primary completion :
    07/01/2011
    Completion :
    07/01/2011
    UGT1A1
    |
    UGT1A1*1*1
    |
    oxaliplatin • irinotecan • Estybon (rigosertib)